Nasdaq:US$15.66 (+1.18) | HKEX:HK$24.70 (+0.70) | AIM:£2.44 (+0.15)
搜索結果
上一篇文章   |   下一篇文章
公告及新聞稿, 腫瘤學 / 免疫學 | 2008-02-29

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate